News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Univest Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) and its officers, alleging violations of federal securities laws. The lawsuit claims that Embecta made false and misleading statements regarding its business, operations, and prospects between November 25, …
Caligan Partners LP and David Johnson have reported a beneficial ownership stake of 5.9% in Cellectar Biosciences (CLRB), amounting to 469,998 shares. This ownership is held through Caligan-managed funds and accounts, with shared voting and dispositive power. The percentage is based on 7,991,812 shares …
SilverArc Capital Management, LLC and Devesh Gandhi have reported a beneficial ownership of 9.99% in Cellectar Biosciences Inc. Class A Common Stock, totaling 851,285 shares. This disclosure, made via a SCHEDULE 13G SEC filing, indicates shared voting and dispositive power over these shares. The …
Faruqi & Faruqi, LLP is reminding Embecta (EMBC) investors of the August 17, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Embecta made misleading statements regarding its financial guidance, particularly concerning its pen needle …
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit stems from Embecta's Q2 2026 financial results, which were significantly below …
The Gross Law Firm has issued a shareholder alert regarding a securities class action against Embecta Corp. (NASDAQ: EMBC). Shareholders who purchased EMBC shares between November 25, 2025, and May 4, 2026, are encouraged to contact the firm, as the company is accused of …
Embecta's President, Devdatt Kurdikar, recently purchased US$141k worth of company stock at US$4.70 per share, increasing his holding by 3.9%. This is the largest insider purchase in the last year, suggesting optimism for the company's future, despite the overall insider ownership being relatively low …
Embecta Corp.'s Senior Vice President and CFO, Jacob Elguicze, recently purchased 20,000 shares of the company's common stock for $93,360. This insider purchase comes after a significant stock decline but a recent rebound, with the company trading at a low P/E ratio. The purchase …
Balyasny Asset Management and affiliated entities have disclosed a 9.99% beneficial ownership stake in Cellectar Biosciences (CLRB) through a Schedule 13G SEC filing. This stake comprises 220,000 common shares and 578,382 shares issuable upon the exercise of warrants, all held under a 9.99% Beneficial …
Kaplan Fox & Kilsheimer LLP is alerting investors of Embecta Corp. (NASDAQ: EMBC) about a class action lawsuit filed against the company. The lawsuit, on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026, alleges that Embecta misrepresented its …
Bleichroeder entities, led by Bleichroeder LP and Andrew Gundlach, have reported a 9.99% equity stake in Cellectar Biosciences (CLRB), amounting to 808,300 common shares. Bleichroeder LP, a registered investment adviser, holds these shares for various advisory clients, granting them sole voting and dispositive power …
Cellectar Biosciences (CLRB) reported a wider-than-expected diluted loss of $0.57 per share for Q2 2026, missing analyst estimates. Despite this, the net loss of $6.9M represents an 83.2% improvement year-over-year. The clinical-stage biopharmaceutical company maintains strong analyst support for its oncology pipeline.
Rosen Law Firm has issued a reminder to investors regarding a class action lawsuit against Embecta Corp. (NASDAQ: EMBC). The lawsuit alleges that Embecta made misleading statements about its fiscal results and its pen needle business, causing investors to suffer damages. Shareholders who wish …
Embecta director Robert J. Hombach recently acquired 45,000 shares of the company's common stock for a total of $223,848. This insider purchase comes as the stock has seen a 36% surge in the past week, despite being significantly down from six months ago. The …
Embecta Corp.'s Senior Vice President and CFO, Jacob Elguicze, purchased 20,000 shares of the company's common stock on August 12, 2026, at a price of $4.668 per share. This open-market transaction increased his direct holdings to 309,138.604 shares. The purchase was not made under …
Cellectar Biosciences reported a wider-than-expected Q2 2026 loss of $0.57 per share, but its stock rose in premarket trading due to a stronger cash position and clinical progress for its lead drug, iopofosine I-131, in Waldenstrom’s macroglobulinemia (WM). The company secured up to $140 …
Schall, Brown & Schwartz LLP (SBS) has reminded investors of a class action lawsuit against Embecta Corp. (EMBC) for alleged violations of securities laws. The lawsuit claims Embecta made false and misleading statements regarding its fiscal guidance for Q2 and full-year 2026, failing to …
(RTTNews) - Cellectar Biosciences, Inc. (CLRB) reported second-quarter 2026 results, highlighting increased R&D investment and a stronger balance sheet compared to the prior year. The company advanced its oncology pipeline with progress in pivotal and early-stage trials, while preparing for a Phase 3 confirmatory …
Cellectar Biosciences reported a net loss of $6.9 million for Q2 2026, an increase from $5.4 million in Q2 2025, driven by higher R&D expenses. The company's cash and cash equivalents rose to $34.0 million, up from $13.2 million at the end of 2025, …
Cellectar Biosciences reported its Q2 2026 financial results, including a $6.9 million net loss, and provided significant corporate updates. The company is advancing its radiotherapeutic pipeline, most notably initiating site activation for a Phase 3 confirmatory trial for iopofosine I 131 in Waldenström macroglobulinemia, …
Cellectar Biosciences announced its second-quarter 2026 financial results and provided a corporate update, highlighting progress in its oncology pipeline. Key developments include the initiation of site activation for a confirmatory Phase 3 study of iopofosine I 131 in Waldenström Macroglobulinemia (WM), with an NDA …
Cellectar Biosciences reported a consolidated net loss of $(12.6M) and diluted loss per share of $(1.52) for the six months ended June 30, 2026. The company remains pre-revenue but achieved clinical milestones including positive Phase 2 results for CLOVER WaM and FDA Breakthrough Therapy …
Search by ticker symbol or company name and select a result to open its chart.